☰

Brian Finan, Ph.D.

Affiliations: 
2011 Biochemistry Indiana University, Bloomington, Bloomington, IN, United States 
Area:
endocrinology, specifically diabetes
Google:
"Brian Finan"
Mean distance: 9.68
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Richard DiMarchi grad student 2011 Indiana University Bloomington
 (Peptide targeting of nuclear hormone action leads to enhanced efficacy and safety in the treatment of the metabolic syndrome.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sánchez-Garrido MA, Serrano-López V, Ruiz-Pino F, et al. (2024) Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nature Communications. 15: 8498
Sachs S, Götz A, Finan B, et al. (2024) Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology. 23: 341
Zaykov AN, Gelfanov VM, Tagmose TM, et al. (2024) Toward once-monthly insulin therapy synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylation. Rsc Chemical Biology. 5: 763-775
Petersen J, Ludwig MQ, Juozaityte V, et al. (2024) GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature
Akindehin S, Liskiewicz A, Liskiewicz D, et al. (2024) Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular Metabolism. 83: 101915
Liskiewicz A, Khalil A, Liskiewicz D, et al. (2023) Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature Metabolism
Sachs S, Götz A, Finan B, et al. (2023) GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology. 22: 217
Campbell JE, Müller TD, Finan B, et al. (2023) GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metabolism
Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, et al. (2023) 100 years of glucagon and 100 more. Diabetologia. 66: 1378-1394
El K, Douros JD, Willard FS, et al. (2023) The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism
See more...